Orphan disease gains second treatment option.
Morrow
Thomas
T
Value-Based Health Department, Genentech Inc.
D001565:Benzoates / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000191:economics / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D035583:Rare Diseases / Q000188:drug therapy* / Q000235:genetics; D011961:Receptors, Fc / Q000008:administration & dosage / Q000819:agonists / Q000235:genetics / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin
D001565:Benzoates; D002352:Carrier Proteins; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag